1Jemal A,Tiwarik R, Murray T,et al. Cancer statistics,2004[ J]. CA Cancer J Clin, 2004,54(15) : 8 -29.
2Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase Ⅱ clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group[J]. J Clin Oncol, 1999, 17(6) : 3461 - 3467.
3Isaaes JS, Xu W, Neekers L. Heat shock protein 90 as a molecular target for cancer therapecititic [ J ]. Cancer Cell, 2003,3 (3) : 213 -217.
4Rocchi P, So A, Kojima,et al. Heat shock protein 27 increases after androgen ablation and plays a eytoprotective role in hormone-refractory prostate cancer [ J ]. Cancer Res,2004,64 ( 18 ) : 6595 - 6602.
5Masahiko K, Kazndo O. Effects of hyperthermia and differentiation on cuhured dunnosteosarcoma cells [ J ]. Cancer Detection and Prevention,2004 ,27( 1 ) :76 - 81.
6Li G, Man H, Ruan X, et al. Association of heat-induced conformational chang with acitivity loss of Rubisco [ J ]. Biochem Biophys Res Commun, 2002,290(3) : 1128 -1132.
